McManus Eileen J, Poke Gemma, Phillips Matthew Cl, Asztely Fredrik
Basic Trainee/Neurology Registrar, Waikato General Hospital, Hamilton, Waikato.
Clinical Geneticist, Capital & Coast District Health.
N Z Med J. 2020 Apr 24;133(1513):116-118.
Perry syndrome is a rare neurological condition characterised clinically by depression, sleep disturbance, central hypoventilation and parkinsonism. Perry syndrome is a TAR DNA-binding protein 43 (TDP-43) proteinopathy associated with mutated dynactin-1 protein, inherited in an autosomal dominant manner. Several pathogenic mutations in exon 2 in the dynactin 1 gene have been identified; p. F521, p. G67d, p. G71R, p. G71E, p. G71A, p. T72p, p. Q74p and p. Y78C. We present the second known case Perry syndrome with confirmed DCTN1 mutation (p. Y78C) in New Zealand, who initially was thought to have a depressive illness. Perry syndrome should be considered in the differential diagnosis of young parkinsonism, especially if there is family history of sleep disorders, weight loss and/or marked depression.
佩里综合征是一种罕见的神经系统疾病,临床特征为抑郁、睡眠障碍、中枢性通气不足和帕金森症。佩里综合征是一种与动力蛋白1(dynactin-1)蛋白突变相关的TAR DNA结合蛋白43(TDP-43)蛋白病,以常染色体显性方式遗传。已在动力蛋白1基因的外显子2中鉴定出几种致病突变;即p.F521、p.G67d、p.G71R、p.G71E、p.G71A、p.T72p、p.Q74p和p.Y78C。我们报告了新西兰第二例经证实存在DCTN1突变(p.Y78C)的佩里综合征病例,该患者最初被认为患有抑郁症。在对年轻帕金森症进行鉴别诊断时应考虑佩里综合征,尤其是存在睡眠障碍、体重减轻和/或明显抑郁家族史的情况。